GENOME WEB, CHICAGO, IL, September 1, 2022 – – After nine years in business, precision medicine company AMPEL BioSolutions is broadening its market from pharmaceutical companies to healthcare providers and their patients.
This summer, the firm had an early-access release of a series of gene expression tests coupled with analysis and clinical decision support, starting with LuGene®, a blood test for systemic lupus erythematosus, and DermaGene®, a skin biopsy test to differentiate between several dermatological conditions including psoriasis, scleroderma, and atopic dermatitis.
{iframe}https://www.genomeweb.com/informatics/ampel-biosolutions-enters-mdx-market-lupus-dermatology-gene-expression-assays#.YxNJmuzMLKo{/iframe}